Arcus biosciences announces new employment inducement grants

Hayward, calif.--(business wire)--arcus biosciences, inc. (nyse:rcus), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the compensation committee of the company's board of directors granted five new employees options to purchase a total of 165,300 shares of the company's common stock at an exercise price per share of $38.19, which was the closing price on january 25, 2021. the stock options were granted pursuant to the company
RCUS Ratings Summary
RCUS Quant Ranking